2023 Q2 Form 10-Q Financial Statement

#000121390023039063 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $13.66K
YoY Change -100.0% -100.0%
Cost Of Revenue $12.94K
YoY Change
Gross Profit $720.00
YoY Change
Gross Profit Margin 5.27%
Selling, General & Admin $1.801M $2.116M $2.405M
YoY Change -41.51% -12.02% 337.63%
% of Gross Profit 334063.89%
Research & Development $2.028M $1.096M
YoY Change
% of Gross Profit
Depreciation & Amortization $162.3K $4.179K $5.010K
YoY Change 1403.8% -16.59%
% of Gross Profit 695.83%
Operating Expenses $3.829M $3.213M $2.405M
YoY Change 24.37% 33.56% 337.63%
Operating Profit -$3.829M -$3.213M -$2.405M
YoY Change 24.3% 33.6% 337.5%
Interest Expense -$117.2K $6.388K $785.3K
YoY Change -127.79% -99.19%
% of Operating Profit
Other Income/Expense, Net $110.0K -$50.00K $45.00K
YoY Change -73.92% -211.11%
Pretax Income -$3.598M -$3.266M -$1.574M
YoY Change 35.35% 107.45% 186.43%
Income Tax
% Of Pretax Income
Net Earnings -$3.763M -$3.538M -$1.574M
YoY Change 41.56% 124.72% 186.43%
Net Earnings / Revenue -11524.45%
Basic Earnings Per Share -$0.01 -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$68.42K
COMMON SHARES
Basic Shares Outstanding 26.13M shares 26.13M shares 23.01M shares
Diluted Shares Outstanding 26.13M shares 26.07M shares 23.01M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.77M $29.91M $50.32M
YoY Change -44.16% -40.55% 4599.71%
Cash & Equivalents $26.65M $29.91M $50.32M
Short-Term Investments $122.5K
Other Short-Term Assets $452.2K $263.0K $628.7K
YoY Change 468.12% -58.17% 806.1%
Inventory
Prepaid Expenses $814.6K $835.8K
Receivables $120.0K
Other Receivables $0.00 $15.78K
Total Short-Term Assets $28.04M $31.11M $50.95M
YoY Change -42.33% -38.93% 4368.78%
LONG-TERM ASSETS
Property, Plant & Equipment $173.3K $174.9K $128.6K
YoY Change 2.21% 35.99%
Goodwill $1.263M $1.263M
YoY Change -67.06%
Intangibles $8.256M $8.414M
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $619.3K
YoY Change -100.0%
Total Long-Term Assets $10.11M $10.93M $128.6K
YoY Change 129.13% 8399.13%
TOTAL ASSETS
Total Short-Term Assets $28.04M $31.11M $50.95M
Total Long-Term Assets $10.11M $10.93M $128.6K
Total Assets $38.15M $42.04M $51.08M
YoY Change -28.06% -17.69% 4380.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.930M $1.448M $433.7K
YoY Change 127.41% 233.78% 81.12%
Accrued Expenses $170.0K $165.0K
YoY Change 67.62%
Deferred Revenue
YoY Change
Short-Term Debt $130.0K $264.1K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.229M $2.122M $433.7K
YoY Change 134.61% 389.34% 81.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $330.0K $787.6K $667.5K
YoY Change -45.37% 18.0%
Total Long-Term Liabilities $330.1K $787.6K $667.5K
YoY Change -45.35% 18.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.229M $2.122M $433.7K
Total Long-Term Liabilities $330.1K $787.6K $667.5K
Total Liabilities $2.559M $2.910M $1.101M
YoY Change 64.67% 164.24% 359.88%
SHAREHOLDERS EQUITY
Retained Earnings -$26.66M -$22.89M
YoY Change 313.48%
Common Stock $18.00K $18.00K
YoY Change -0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.59M $39.14M $49.98M
YoY Change
Total Liabilities & Shareholders Equity $38.15M $42.04M $51.08M
YoY Change -28.06% -17.69% 4380.07%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.763M -$3.538M -$1.574M
YoY Change 41.56% 124.72% 186.43%
Depreciation, Depletion And Amortization $162.3K $4.179K $5.010K
YoY Change 1403.8% -16.59%
Cash From Operating Activities -$3.479M -$3.386M -$2.527M
YoY Change 46.37% 33.96% 561.9%
INVESTING ACTIVITIES
Capital Expenditures $3.110K $53.89K -$113.9K
YoY Change -108.12% -147.32%
Acquisitions
YoY Change
Other Investing Activities $347.1K $4.190K
YoY Change 350.45%
Cash From Investing Activities $344.0K -$49.70K -$113.9K
YoY Change 787.77% -56.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -130.8K 264.1K
YoY Change
NET CHANGE
Cash From Operating Activities -3.479M -3.386M -2.527M
Cash From Investing Activities 344.0K -49.70K -113.9K
Cash From Financing Activities -130.8K 264.1K
Net Change In Cash -3.266M -$3.174M $0.00
YoY Change 39.68%
FREE CASH FLOW
Cash From Operating Activities -$3.479M -$3.386M -$2.527M
Capital Expenditures $3.110K $53.89K -$113.9K
Free Cash Flow -$3.482M -$3.440M -$2.414M
YoY Change 48.9% 42.51% 532.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40804
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1591963
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Lincoln Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Miami Beach
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33139
CY2023Q1 dei City Area Code
CityAreaCode
(702)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
514-4174
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26126740 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29914063 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33087864 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
15782 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
835777 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
562375 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
262992 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
262992 usd
CY2023Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
84703 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
163463 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
31113317 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
34076693 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174906 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125197 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
460539 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
500428 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8413937 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8571478 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1262911 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1262911 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
619287 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
643382 usd
CY2023Q1 us-gaap Assets
Assets
42044897 usd
CY2022Q4 us-gaap Assets
Assets
45180089 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1447539 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1481393 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
264103 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164974 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
160362 usd
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
245544 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
235879 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2122160 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1877634 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
300480 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
344021 usd
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
187481 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
140611 usd
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
299669 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
319575 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
787630 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
804207 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2909790 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2681841 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
495000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
495000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26126740 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26126740 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26043406 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26043406 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
17995 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
17987 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62014815 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61837802 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3144 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-661 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22894559 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19356880 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
39135107 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42498248 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42044897 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45180089 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2116266 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2078878 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1096286 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3212552 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2078878 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
46870 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-785297 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
6388 usd
CY2023Q1 us-gaap Other Income
OtherIncome
-53258 usd
CY2022Q1 us-gaap Other Income
OtherIncome
785297 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3265810 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1293581 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3265810 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1293581 usd
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-271869 usd
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-280659 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3537679 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1574240 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26073036 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23008371 shares
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.06
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3537679 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1574240 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2483 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1574240 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3540162 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3148480 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51420501 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
26540 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
94295 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
14795 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4513 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1574240 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49977378 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42498248 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
23650 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153371 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2483 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3537679 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
39135107 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3265810 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1293581 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4179 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
157541 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
177021 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
135630 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
46870 usd
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-785297 usd
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
960 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-15782 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
273402 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
238462 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-33855 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29553 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3202278 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2152158 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
53888 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1951 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-53888 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1951 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
392354 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
128251 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
264103 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2483 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4513 usd
CY2023Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-183444 usd
CY2022Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-411252 usd
CY2023Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
4189 usd
CY2022Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-106544 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3173801 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2676419 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33087864 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52901962 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29914063 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50225544 usd
CY2023Q1 us-gaap Cash
Cash
29900000 usd
CY2023Q1 ktta Working Capital
WorkingCapital
29200000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Management regularly makes estimates related to the fair value of warrant liabilities; the recoverability of long-lived assets; the fair values and useful lives of intangible assets acquired in business combinations; the potential impairment of goodwill; and income taxes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable, the results of which form the basis for the amounts recorded in the condensed consolidated financial statements. As appropriate, the Company obtains reports from third-party valuation experts to inform and support estimates related to fair value measurements.</span></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white"> </span></p>
CY2023Q1 ktta Grant Income To Related Party
GrantIncomeToRelatedParty
10000000 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of March 31, 2023, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q1 us-gaap Other Cash Equivalents At Carrying Value
OtherCashEquivalentsAtCarryingValue
10001263 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
176000 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
11481 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
132000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8611 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2180000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
15356000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
12600000 shares
CY2023Q1 ktta Restricted Stock Units
RestrictedStockUnits
116666 shares
CY2022Q1 ktta Restricted Stock Units
RestrictedStockUnits
200000 shares
CY2023Q1 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
1.2364 pure
CY2022Q4 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
1.2039 pure
CY2023Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.2152 pure
CY2022Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.2362 pure
CY2023Q1 ktta Foreign Currency Exchange Rate Remeasurements
ForeignCurrencyExchangeRateRemeasurements
0.92 pure
CY2022Q4 ktta Foreign Currency Exchange Rate Remeasurements
ForeignCurrencyExchangeRateRemeasurements
0.9367 pure
CY2023Q1 ktta Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
0.932 pure
CY2022Q4 ktta Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
0.9517 pure
CY2023Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
184247000 usd
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
128756000 usd
CY2023Q1 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
9341000 usd
CY2022Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3559000 usd
CY2023Q1 us-gaap Property Plant And Equipment Owned Net
PropertyPlantAndEquipmentOwnedNet
174906000 usd
CY2022Q4 us-gaap Property Plant And Equipment Owned Net
PropertyPlantAndEquipmentOwnedNet
125197000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
569000 usd
CY2023Q1 us-gaap General Fair Value Hedge Information Minimum R Square Percentage
GeneralFairValueHedgeInformationMinimumRSquarePercentage
0.078 pure
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
460539 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
500428 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164974 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
160362 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
300480 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
344021 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
55242 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
168812 usd
CY2022 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
169695 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
146024 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
199872 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
183216 usd
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
529112 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63658 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
465454 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
472623 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
630164 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
630164 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
630164 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
630164 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5420657 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8413937 usd
CY2023Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
83334 shares
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24000 usd
CY2023Q1 ktta Shares Of Common Stock
SharesOfCommonStock
880000 shares
CY2023Q1 ktta Common Stock Par Value Per Share
CommonStockParValuePerShare
0.491
CY2023Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P10Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
288000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6864 pure
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
776000 usd
CY2023Q1 ktta Fair Value Of Representative Warrants
FairValueOfRepresentativeWarrants
0.042
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
15356000 shares
CY2023Q1 ktta Weightedaverage Remaining Contractual Termyears
WeightedaverageRemainingContractualTermyears
P3Y8M8D
CY2023Q1 ktta Weightedaverage Exercise Price
WeightedaverageExercisePrice
4.12
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16634 usd
CY2023Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
28887 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
39182 usd
CY2023Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
84703 usd
CY2023Q1 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
248597 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
355356 usd
CY2023Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
15334 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
619287 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
703990 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
141790 usd
CY2023Q1 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
103754 usd
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
245544 usd
CY2023Q1 us-gaap Lease Deposit Liability
LeaseDepositLiability
299669 usd
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
299669 usd
CY2023Q1 ktta Total Liabilities Of Discontinued Operations
TotalLiabilitiesOfDiscontinuedOperations
545213 usd
CY2022Q1 us-gaap Revenues
Revenues
13658 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12937 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
721 usd
CY2023Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
271869 usd
CY2022Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
326380 usd
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-271869 usd
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-325659 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26073036 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23008371 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Additional Liability Long Duration Insurance After Reinsurance
AdditionalLiabilityLongDurationInsuranceAfterReinsurance
392000 usd
CY2023Q1 us-gaap Short Term Debt Percentage Bearing Variable Interest Rate
ShortTermDebtPercentageBearingVariableInterestRate
0.078 pure
CY2023Q1 ktta Principal Amount
PrincipalAmount
45000 usd
CY2023Q1 us-gaap Borrowings Under Guaranteed Investment Agreements
BorrowingsUnderGuaranteedInvestmentAgreements
264000 usd
CY2022Q4 us-gaap Borrowings Under Guaranteed Investment Agreements
BorrowingsUnderGuaranteedInvestmentAgreements
0 usd
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Pasithea Therapeutics Corp.
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26073036 shares
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
usd
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
CY2023Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
CY2022Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
CY2023Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
usd
CY2023Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
usd
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23008371 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26073036 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001841330

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001213900-23-039063-index-headers.html Edgar Link pending
0001213900-23-039063-index.html Edgar Link pending
0001213900-23-039063.txt Edgar Link pending
0001213900-23-039063-xbrl.zip Edgar Link pending
f10q0323ex31-1_pasitheathe.htm Edgar Link pending
f10q0323ex31-2_pasitheathe.htm Edgar Link pending
f10q0323ex32-1_pasitheathe.htm Edgar Link pending
f10q0323ex32-2_pasitheathe.htm Edgar Link pending
f10q0323_pasitheatherap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ktta-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
ktta-20230331_cal.xml Edgar Link unprocessable
ktta-20230331_def.xml Edgar Link unprocessable
ktta-20230331_lab.xml Edgar Link unprocessable
ktta-20230331_pre.xml Edgar Link unprocessable
f10q0323_pasitheatherap_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending